Explore the words cloud of the CAPRI project. It provides you a very rough idea of what is the project "CAPRI" about.
The following table provides information about the project.
CAPRI MEDICAL LIMITED
|Coordinator Country||Ireland [IE]|
|Total cost||3˙423˙556 €|
|EC max contribution||2˙396˙489 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2020-02-01 to 2022-01-31|
Take a look of project's partnership.
|1||CAPRI MEDICAL LIMITED||IE (GALWAY)||coordinator||2˙396˙489.00|
Persistent postoperative chronic pain (POCP) is defined as pain lasting for two or more months after surgery, when other causes of pain are excluded, such as cancer or chronic infection. The goal of the Capri-Stim project is to develop a product to replace current pain medication and nerve block injectable approaches for chronic pain.
Capri-Stim is the only implant suitable for postoperative pain having an indwell duration of over 5 years with no side effects. Capri-Stim only requires one injection, is a low risk class 2 device, has an average selling price (ASP) of 50% less than current competitors. Capri-Stim enables the patient being discharged from the healthcare system after one visit and self managed from home. The technology is protected by 4 patent filings
Pain medication is addictive and comes with significant side effects. Nerve block injectables need to be repeated at least every 3 months and have their own significant side effects. Other technologies have attempted to replace these approaches but have all failed as they all involve significant invasive surgical procedures, are susceptible to lead migration, are too large for intramuscular placement with inaccurate placement causing reduced efficacy.
Developed in NUI-Galway, Capri-Stim is a new product and the only implant suitable for postoperative pain having an indwell duration of over 5 years with no side effects. Capri-Stim only requires one injection, is a low risk class 2 device, has an ASP of 50% less than current competitors. Overall the Capri-Stim product means that the patient can be discharged from the healthcare system after one visit and self managed from home.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAPRI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CAPRI" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
ADVANCED TREATMENT OF CONTAMINATED SOILRead More
IOT and cloud computing for online medical analysis service platformRead More